![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CALU |
Gene summary for CALU |
![]() |
Gene information | Species | Human | Gene symbol | CALU | Gene ID | 813 |
Gene name | calumenin | |
Gene Alias | CALU | |
Cytomap | 7q32.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024R755 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
813 | CALU | GSM4909281 | Human | Breast | IDC | 7.20e-21 | 5.32e-01 | 0.21 |
813 | CALU | GSM4909282 | Human | Breast | IDC | 1.47e-05 | 2.69e-01 | -0.0288 |
813 | CALU | GSM4909285 | Human | Breast | IDC | 7.40e-07 | 2.59e-01 | 0.21 |
813 | CALU | GSM4909286 | Human | Breast | IDC | 2.31e-08 | 2.44e-01 | 0.1081 |
813 | CALU | GSM4909291 | Human | Breast | IDC | 8.42e-09 | 5.00e-01 | 0.1753 |
813 | CALU | GSM4909293 | Human | Breast | IDC | 1.99e-06 | 2.16e-01 | 0.1581 |
813 | CALU | GSM4909296 | Human | Breast | IDC | 4.02e-04 | -3.16e-02 | 0.1524 |
813 | CALU | GSM4909297 | Human | Breast | IDC | 8.78e-06 | -2.05e-01 | 0.1517 |
813 | CALU | GSM4909304 | Human | Breast | IDC | 9.22e-12 | 3.40e-01 | 0.1636 |
813 | CALU | GSM4909311 | Human | Breast | IDC | 1.65e-11 | -2.00e-01 | 0.1534 |
813 | CALU | GSM4909312 | Human | Breast | IDC | 5.85e-03 | -1.55e-02 | 0.1552 |
813 | CALU | GSM4909315 | Human | Breast | IDC | 3.20e-15 | 5.25e-01 | 0.21 |
813 | CALU | GSM4909319 | Human | Breast | IDC | 1.06e-16 | -2.05e-01 | 0.1563 |
813 | CALU | GSM4909321 | Human | Breast | IDC | 1.41e-07 | -2.17e-01 | 0.1559 |
813 | CALU | brca2 | Human | Breast | Precancer | 1.13e-03 | 1.46e-01 | -0.024 |
813 | CALU | brca3 | Human | Breast | Precancer | 1.96e-02 | 1.21e-01 | -0.0263 |
813 | CALU | M2 | Human | Breast | IDC | 2.47e-03 | 3.35e-01 | 0.21 |
813 | CALU | NCCBC14 | Human | Breast | DCIS | 1.14e-06 | -1.03e-02 | 0.2021 |
813 | CALU | NCCBC2 | Human | Breast | DCIS | 9.07e-03 | 2.26e-01 | 0.1554 |
813 | CALU | NCCBC5 | Human | Breast | DCIS | 7.62e-06 | -1.92e-01 | 0.2046 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALU | SNV | Missense_Mutation | c.95N>G | p.Lys32Arg | p.K32R | O43852 | protein_coding | tolerated(0.5) | benign(0.059) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
CALU | SNV | Missense_Mutation | c.624A>G | p.Ile208Met | p.I208M | O43852 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CALU | SNV | Missense_Mutation | novel | c.330N>T | p.Lys110Asn | p.K110N | O43852 | protein_coding | tolerated(0.12) | benign(0.151) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CALU | SNV | Missense_Mutation | novel | c.934N>T | p.Asp312Tyr | p.D312Y | O43852 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CALU | SNV | Missense_Mutation | c.55N>A | p.Ser19Thr | p.S19T | O43852 | protein_coding | tolerated(0.7) | benign(0.013) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CALU | SNV | Missense_Mutation | novel | c.655N>A | p.Glu219Lys | p.E219K | O43852 | protein_coding | tolerated(0.14) | benign(0.093) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
CALU | SNV | Missense_Mutation | rs774816656 | c.895N>A | p.Val299Ile | p.V299I | O43852 | protein_coding | tolerated(0.13) | benign(0.142) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CALU | SNV | Missense_Mutation | c.965A>G | p.Glu322Gly | p.E322G | O43852 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CALU | SNV | Missense_Mutation | novel | c.686A>G | p.Asp229Gly | p.D229G | O43852 | protein_coding | deleterious(0.02) | benign(0.114) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CALU | SNV | Missense_Mutation | rs748187816 | c.257A>G | p.Asp86Gly | p.D86G | O43852 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-DD-AAE7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
813 | CALU | DRUGGABLE GENOME | acenocoumarol | ACENOCOUMAROL | 17596133,29479633 |
Page: 1 |